AI narrows the focus for our brain-targeted cancer drug

Preview text: AI narrows the focus for our brain-targeted cancer drug Plus: join Kim, Mads and Handol…

Friday, Oct 30, 2026 at 11:32 AM EasternMailchimp

Rakovina TherapeuticsAI narrows the focus for our brain-targeted cancer drug

Fit to screenFull size

Using this email in an article? Credit: Rakovina Therapeutics email via They Sent It, with a link to this page. Full-size image

Use this example

Subject: AI narrows the focus for our brain-targeted cancer drug
Preview text: AI narrows the focus for our brain-targeted cancer drug Plus: join Kim, Mads and Handol…
From: ir@rakovinatherapeutics.com
Brand: Rakovina Therapeutics
ESP: Mailchimp
Sent: Fri Oct 30, 2026, 11:32 AM ET
Size: 59 KB
Images: 1
Links: 11, 1 of them buttons
Subject length: 55 characters

Against Rakovina Therapeutics's usual

Sent in the 11 AM hour, which holds 6% of its emails; 31% arrive in the 4 PM hour. The subject is 55 characters; its average is 70.

Email headers

What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.

From: Rakovina Therapeutics <[email protected]>
Reply-To: Rakovina Therapeutics <[email protected]>
Subject: AI narrows the focus for our brain-targeted cancer drug
Date: Fri, 30 Oct 2026 15:32:40 +0000
Message-ID domain: mail93.atl301.rsgsv.net
Return-Path domain: mail93.atl301.rsgsv.net
DKIM signature: d=gmail.mcsv.net s=k2; d=mailchimpapp.net s=k3
Authentication: dkim=pass (gmail.mcsv.net), dkim=pass (mailchimpapp.net), spf=pass (mail93.atl301.rsgsv.net)
List-Unsubscribe: Present, one-click
Mailer: Mailchimp Mailer
Feedback-ID sender: mc

Other sending headers (names only): X-Campaign, X-campaignid, X-Report-Abuse, X-MC-User, X-Accounttype

	Nov 10, 2026 12:27 PM	Announcing our partnership with Artemis AI
	Nov 4, 2026 10:45 AM	Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim
	Oct 30, 2026 11:32 AM	AI narrows the focus for our brain-targeted cancer drug (this email)
	Oct 22, 2026 4:17 PM	kt-5000AI update: what we’ve shown, and what’s next
	Oct 18, 2026 4:14 PM	Rakovina secures exclusivity on kt-5000 target profile · Resent
	Oct 15, 2026 10:30 AM	Rakovina secures exclusivity on kt-5000 target profile
	Oct 1, 2026 4:18 PM	Rakovina partners with Celvion: what it means for our ATR program